Mutations in Differentially Impact Synergy of Meropenem/vaborbactam and Ceftazidime/avibactam in Combination with Other Antibiotics Against KPC-producing

Overview

Journal JAC Antimicrob Resist

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2023 Oct 30

PMID 37901589

Authors

Tara M Rogers

Ellen G Kline

Marissa P Griffith

Chelsea E Jones

Abigail M Rubio

Kevin M Squires

Ryan K Shields

Affiliations

Soon will be listed here.

Abstract

Objectives: Ceftazidime/avibactam and meropenem/vaborbactam are preferred agents for carbapenemase (KPC)-producing (KPC-) infections and are often used in combination with other agents. We aimed to characterize the synergy of combinations against KPC- with varying genotypes.

Methods: KPC- that harboured WT, IS or glycine-aspartic acid duplication (GD) genotypes were selected. MICs were determined in triplicate. Synergy was assessed by time-kill assays for ceftazidime/avibactam and meropenem/vaborbactam in combination with colistin, gentamicin, tigecycline, meropenem or fosfomycin against 1 × 10 cfu/mL KPC-.

Results: KPC- harboured WT ( = 5), IS ( = 5) or GD ( = 5); 11 were KPC-2 and 4 were KPC-3. All were susceptible to ceftazidime/avibactam and meropenem/vaborbactam. In time-kill analysis, ceftazidime/avibactam and meropenem/vaborbactam 1 × MIC exhibited mean 24 h log-kills of -2.01 and -0.84, respectively. Ceftazidime/avibactam was synergistic in combination with colistin independent of genotype. Ceftazidime/avibactam combinations impacted by porin mutations (compared to WT) were meropenem (-5.18 versus -6.62 mean log-kill, < 0.001) and fosfomycin (-3.98 versus -6.58, = 0.058). Mean log-kills with meropenem/vaborbactam were greatest in combination with gentamicin (-5.36). In the presence of porin mutations, meropenem/vaborbactam killing activity was potentiated by the addition of colistin (-6.65 versus -0.70, = 0.03) and fosfomycin (-3.12 versus 1.54, = 0.003).

Conclusions: Our results shed new light on the synergy of ceftazidime/avibactam and meropenem/vaborbactam combinations against KPC- with or without porin mutations. Killing activity of ceftazidime/avibactam with other cell wall active agents was decreased against isolates with porin mutations. On the other hand, some meropenem/vaborbactam combinations demonstrated enhanced killing in the presence of porin mutations.

Citing Articles

Carbapenem-Resistant in Urinary Tract Infections: From Biological Insights to Emerging Therapeutic Alternatives.

Bologna E, Licari L, Manfredi C, Ditonno F, Cirillo L, Fusco G Medicina (Kaunas). 2024; 60(2).

PMID: 38399502 PMC: 10889937. DOI: 10.3390/medicina60020214.

References

Gottig S, Frank D, Mungo E, Nolte A, Hogardt M, Besier S . Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother. 2019; 74(11):3211-3216. DOI: 10.1093/jac/dkz330. View

Alba J, Ishii Y, Thomson K, Moland E, Yamaguchi K . Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother. 2005; 49(11):4760-2. PMC: 1280115. DOI: 10.1128/AAC.49.11.4760-4762.2005. View

Bassetti M, Giacobbe D, Giamarellou H, Viscoli C, Daikos G, Dimopoulos G . Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2017; 24(2):133-144. DOI: 10.1016/j.cmi.2017.08.030. View

Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith D . Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017; 61(11). PMC: 5655098. DOI: 10.1128/AAC.01443-17. View

Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M . Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clin Infect Dis. 2021; 73(9):1664-1676. DOI: 10.1093/cid/ciab176. View

Wong J, Romano M, Kerry L, Kwong H, Low W, Brett S . OmpK36-mediated Carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo. Nat Commun. 2019; 10(1):3957. PMC: 6718652. DOI: 10.1038/s41467-019-11756-y. View

Wang H, Gu X, Weng Y, Xu T, Fu Z, Peng W . Quantitative analysis of pathogens in the lower respiratory tract of patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2015; 15:94. PMC: 4543462. DOI: 10.1186/s12890-015-0094-z. View

Tilanus A, Drusano G . Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time. Open Forum Infect Dis. 2023; 10(7):ofad305. PMC: 10319623. DOI: 10.1093/ofid/ofad305. View

Oliva A, Volpicelli L, Di Bari S, Curtolo A, Borrazzo C, Cogliati Dezza F . Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing : results from a multicentre retrospective study. JAC Antimicrob Resist. 2022; 4(6):dlac121. PMC: 9728520. DOI: 10.1093/jacamr/dlac121. View

10.

Shields R, Clancy C, Hao B, Chen L, Press E, Iovine N . Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother. 2015; 59(9):5793-7. PMC: 4538547. DOI: 10.1128/AAC.00548-15. View

11.

Mikhail S, Singh N, Kebriaei R, Rice S, Stamper K, Castanheira M . Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019; 63(8). PMC: 6658738. DOI: 10.1128/AAC.00779-19. View

12.

Oliva A, Curtolo A, Volpicelli L, Cogliati Dezza F, De Angelis M, Cairoli S . Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside. Antibiotics (Basel). 2021; 10(7). PMC: 8300652. DOI: 10.3390/antibiotics10070781. View

13.

Cremieux A, Dinh A, Nordmann P, Mouton W, Tattevin P, Ghout I . Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2019; 74(9):2666-2675. DOI: 10.1093/jac/dkz257. View

14.

David S, Wong J, Sanchez-Garrido J, Kwong H, Low W, Morecchiato F . Widespread emergence of OmpK36 loop 3 insertions among multidrug-resistant clones of Klebsiella pneumoniae. PLoS Pathog. 2022; 18(7):e1010334. PMC: 9302836. DOI: 10.1371/journal.ppat.1010334. View

15.

Wang F, Zhou Q, Yang X, Bai Y, Cui J . Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment. PLoS One. 2021; 16(10):e0258426. PMC: 8516195. DOI: 10.1371/journal.pone.0258426. View

16.

Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C . Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance.... Clin Infect Dis. 2022; 75(2):187-212. PMC: 9890506. DOI: 10.1093/cid/ciac268. View

17.

Bhavnani S, Trang M, Griffith D, Lomovskaya O, Hammel J, Loutit J . Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints. Antimicrob Agents Chemother. 2022; 66(12):e0213021. PMC: 9764998. DOI: 10.1128/aac.02130-21. View

18.

Paul M, Carrara E, Retamar P, Tangden T, Bitterman R, Bonomo R . European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2021; 28(4):521-547. DOI: 10.1016/j.cmi.2021.11.025. View

19.

Clancy C, Chen L, Shields R, Zhao Y, Cheng S, Chavda K . Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 2013; 13(10):2619-33. PMC: 3955300. DOI: 10.1111/ajt.12424. View

20.

Rogers T, Kline E, Griffith M, Jones C, Rubio A, Squires K . Impact of genotype and KPC subtype on the activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing clinical isolates. JAC Antimicrob Resist. 2023; 5(2):dlad022. PMC: 10035640. DOI: 10.1093/jacamr/dlad022. View